Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Idiopathic pulmonary fibrosis].

Vincent Cottin1, Jean-François Cordier

  • 1Service de pneumologie, Centre de référence des maladies orphelines pulmonaires, hôpital Louis Pradel, Hospices civils de Lyon, UMR 754, université Lyon I, Bron. vincent.cottin@chu-lyon.fr

La Revue Du Praticien
|August 15, 2006
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a serious lung disease with no cure. While a new treatment shows modest improvement, more clinical trials are urgently needed for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Syndrome of pleural and retrosternal "bridging" fibrosis and retroperitoneal fibrosis in patients with asbestos exposure.

BMJ case reports·2025
Same author

A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2020
Same author

Pilot experience of multidisciplinary team discussion dedicated to inherited pulmonary fibrosis.

Orphanet journal of rare diseases·2019
Same author

Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients.

The Journal of rheumatology·2019
Same author

Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France.

Chest·2019
Same author

Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry.

Frontiers in neurology·2019

Area of Science:

  • Pulmonology
  • Pathology
  • Radiology

Context:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease.
  • Characterized by interstitial fibrosis, fibroblastic foci, and honeycomb lung.
  • Diagnosis relies on clinical, radiological, and pathological findings.

Purpose:

  • To outline the diagnostic criteria for IPF.
  • To review current treatment strategies and their limitations.
  • To emphasize the need for further research and clinical trials.

Summary:

  • IPF diagnosis integrates clinical, HRCT, and biopsy findings (usual interstitial pneumonia pattern).
  • A typical HRCT pattern allows diagnosis without biopsy in 50% of cases.
  • No current treatment improves survival; N-acetylcysteine with corticosteroids/azathioprine shows modest functional benefit.

Impact:

  • Highlights the diagnostic challenges and limitations of current IPF treatments.
  • Underscores the urgent need for effective therapies and clinical trials.
  • Aims to improve understanding and management of this debilitating disease.

Related Experiment Videos